Abstract:Objective:To evaluate the effect of Schisandrin B (Sch B) on the sensitivity to neoadjuvant chemotherapy in rats with glioma.Methods:Seventy-two healthy male Wistar rats, weighing 180-200 g, were divided into 6 groups ( n=12 each) using a random number table method: sham operation group (group Sham), glioma group (group G), neoadjuvant chemotherapy group (group T), Sch B 10 mg/kg plus neoadjuvant chemotherapy group (group S 1+ T), Sch B 20 mg/kg plus neoadjuvant chemotherapy group (group S 2+ T), and Sch B 40 mg/kg plus neoadjuvant chemotherapy group (group S 3+ T). C6 glioma cell suspension 10 μl was injected into the right caudate nucleus to establish the glioma model.Temozolomide 25 mg/kg was given intragastrically starting from the 10th day after establishing the model for 6 consecutive days in group T. Sch B 10, 20 and 40 mg/kg and temozolomide 25 mg/kg were given intragastrically starting from the 10th day after establishing the model for 6 consecutive days in S 1+ T, S 2+ T and S 3+ T groups, respectively.At 18 days after the model was established, 6 rats from each group were selected, and the tumors were isolated and weighed.The core area of tumors was removed to detect the expression of matrix metalloprotein-2 (MMP-2), MMP-9 and glutathione peroxidase (GPX4) using Western blot.The survival time of rats left in each group was recorded. Results:Compared with group Sham, the survival time was significantly shortened, and the expression of MMP2, MMP9 and GPX4 was up-regulated in the other five groups ( P<0.05). Compared with group G, the weight of glioma was significantly decreased, the survival time was prolonged, and the expression of MMP2, MMP9 and GPX4 was down-regulated in T, S 1+ T, S 2+ T and S 3+ T groups ( P<0.05). Compared with group T, the weight of glioma was significantly decreased, the survival time was prolonged, and the expression of MMP2, MMP9 and GPX4 was down-regulated in S 1+ T, S 2+ T and S 3+ T groups ( P<0.05). Compared with group S 2+ T, the weight of glioma was significantly increased, the survival time was shortened, and the expression of MMP2, MMP9 and GPX4 was up-regulated in S 1+ T and S 3+ T groups ( P<0.05). There was no significant difference in the parameters mentioned above between group S 1+ T and group S 3+ T ( P>0.05). Conclusion:Schisandrin B can enhance the sensitivity to neoadjuvant chemotherapy in rats with glioma, which may be related to inhibition of tumor invasion and metastasis and promotion of ferroptosis, and 20 mg·kg -1·d -1 has the best effect.

Amplication Influence of Deoxyschizandrin Towards Adverse Effect of Glioma Therapeutic Drug Irinotecan

Enhanced Proliferation Inhibition and Apoptosis in Glioma Cells Elicited by Combination of Irinotecan and Imatinib

Intestinal Toxicity of Irinotecan and Its Clinical Prevention

Ott_a_240803 2807..2817

Inhibition of SN-38 glucuronidation by gefitinib and its metabolite

Preventive Effects of a Chinese Herbal Formula, Shengjiang Xiexin Decoction, on Irinotecan-Induced Delayed-Onset Diarrhea in Rats

Drug-Drug Interactions and Disease Status Are Associated with Irinotecan-Induced Hepatotoxicity: A Cross-Sectional Study in Shanghai.

The Effect and Mechanism of Erianin on the Reversal of Oxaliplatin Resistance in Human Colon Cancer Cells.

Study on schizandrin A reversing drug resistance of glioma stem/progenitor cells by ATP binding cassette subfamily B member 1

Targeted inhibition of Gus-expressing Enterococcus faecalis to promote intestinal stem cell and epithelial renovation contributes to the relief of irinotecan chemotoxicity by dehydrodiisoeugenol

Uridine Diphosphate Glucuronide Transferase 1a1fnx0128 Gene Polymorphism and the Toxicity of Irinotecan in Recurrent and Refractory Small Cell Lung Cancer.

Contribution of HIF-1α/BNIP3-mediated autophagy to lipid accumulation during irinotecan-induced liver injury

THE EFFECT OF IRISQUINONE ON THE GLUTATHIONE SYSTEM AND MRP EXPRESSION OF CISPLATIN-RESISTANT HUMAN LUNG ADENOCARCINOMA CELL LINE (A549DDP)

Effect of Schisandrin B on sensitivity to neoadjuvant chemotherapy in rats with glioma

Divergent Actions of Pyruvate and ATP in Glucose-mediated Irinotecan Chemoresistance in Colorectal Cancer

Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A1 * 6 or UGT1A1 * 28.

Mechanisms and Emerging Strategies for Irinotecan-Induced Diarrhea

Amino Acid Metabolism Abnormity and Microenvironment Variation Mediated Targeting and Controlled Glioma Chemotherapy.

The Pharmacokinetic Interaction Between Irinotecan and Sunitinib

UGT1A1 Genotype-Guided Irinotecan Dosing During Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Prospective Analysis of SN-38 Concentration

Pharmacometabolomic Prediction of Individual Differences of Gastrointestinal Toxicity Complicating Myelosuppression in Rats Induced by Irinotecan.